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Received February 22, 2012; accepted April 30, 2012AbstractBackground: The optimal treatment for tonsillar squamous cell carcinoma (SCC) remains controversial. The purpose of this study was to
evaluate long-term treatment outcomes of patients with tonsillar SCC, in order to aid in appropriate treatment selection.
Methods: We conducted a retrospective chart review of 105 patients with curatively treated tonsillar SCC between January 1996 and December
2005. Forty-three patients (41.0%) underwent primary surgery with or without adjuvant therapy (primary surgery group), and 62 patients
(59.0%) were treated with radiotherapy/chemoradiotherapy (RT/CRT, organ preservation group). Twenty patients (19%) received tumor ton-
sillectomy before definitive RT/CRT and were grouped into the organ preservation group.
Results: No significant differences were observed between the primary surgery and organ preservation groups in terms of local control
( p ¼ 0.212), regional control ( p ¼ 0.684), distant metastasis ( p ¼ 0.627), 5-year disease-specific survival (DSS, p ¼ 0.774), and overall survival
rates (OS, p ¼ 0.667). The rates of major complication ( p ¼ 0.216), long-term dependency on feeding tubes ( p ¼ 0.876), and tracheostomy
( p ¼ 0.401) were also similar. Advanced T classification (T3e4) was the only factor associated with significantly worse DSS ( p ¼ 0.007) and
OS ( p ¼ 0.012). However, there was also no difference in final treatment outcomes in T3e4 patients regardless of whether they were treated
with primary surgery or RT/CRT. In the organ preservation group, tumor tonsillectomy before RT/CRT did not improve local control ( p ¼ 0.520)
or other treatment outcomes, including 5-year DSS ( p ¼ 0.707) and OS ( p ¼ 0.745).
Conclusion: Both primary surgery and RT/CRT organ preservation are effective treatments for tonsillar SCC. Single modality treatment, either
surgery or RT/CRT, can typically be provided for stage IeII diseases. Although RT/CRT organ preservation is used more frequently for stage
IIIeIV tonsillar SCC in recent years, primary surgery combined with adjuvant therapy still achieves equivalent outcomes. Multidisciplinary
pretreatment counseling and the facilities and personnel available are therefore important for decision-making. In addition, if RT/CRT organ
preservation is selected as the primary treatment, tumor tonsillectomy is not indicated.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Tonsillar squamous cell carcinoma (SCC) is the most
common type of oropharyngeal cancer and is relatively radi-
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http://dx.doi.org/10.1016/j.jcma.2012.12.007including primary surgery with or without adjuvant therapy
and radiotherapy/chemoradiotherapy (RT/CRT) organ preser-
vation. Early tonsillar SCC can be effectively treated with
either RT or surgery alone.2 Many patients, however, present at
advanced stages, and a combination of primary surgery and
postoperative radiotherapy (PORT) is the traditional treatment
of choice.3,4
Over the past decade, however, there has been a paradigm
shift toward RT/CRT organ preservation because surgicalhinese Medical Association. All rights reserved.
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and frequently associated with post-treatment cosmetic and
functional sequelae.5,6 The combination of chemotherapy with
RT in organ preservation treatment has been demonstrated to
improve the efficacy of RT alone for advanced oropharyngeal
SCC, offering comparable treatment outcomes to primary
surgery with PORT.7e9 However, high rates of acute grade
3e4 toxicities and late treatment sequelae can be observed
under intense CRT treatment, including xerostomia, dyspha-
gia, soft tissue fibrosis, and radionecrosis.10 So far, no ran-
domized studies have compared the treatment outcomes of
CRT and primary surgery for tonsillar SCC, and therefore, the
optimal treatment selection remains unsettled.5,11
Another controversial issue is the benefit of tumor tonsil-
lectomy before RT/CRT organ preservation. Surgical excision
of the primary tumor reduces tumor burden and can theoret-
ically provide better local tumor control. Yildirim et al12
demonstrated that gross primary tumor removal by tonsillec-
tomies followed by RT achieved excellent treatment outcomes.
However, no control group without tonsillectomy was avail-
able for comparison in their study, and the benefit of tumor
tonsillectomy remains unclear.
The purpose of this study was to compare the treatment
outcomes, major complication rates, and functional results of
patients with tonsillar SCC treated with either primary surgery
or RT/CRT organ preservation. Furthermore, we also inves-
tigated the role of tumor tonsillectomy before RT/CRT organ
preservation.
2. Methods2.1. Study populationBetween January 1996 and December 2005, 105 patients
with histologically confirmed tonsillar SCC were curatively
treated at the Department of Otolaryngology, Taipei Veterans
General Hospital, Taiwan. None of the patients had radiologic
evidence of distant metastasis at presentation, and those with
a previous history of cancer were excluded unless they had
been disease free for at least 2 years.
Pretreatment evaluations included a physical examination,
panendoscopy tumor mapping and biopsy, computed tomog-
raphy (CT) or magnetic resonance imaging of the primary
tumor and the neck, chest X-ray or chest CT, and routine lab-
oratory studies. Treatment records were reviewed, and the pa-
tients were categorized into two groups: surgery with or without
adjuvant therapy (primary surgery group) and RT/CRT (organ
preservation group). After treatment completion, the patients
entered a monthly follow-up program for the 1st year, and every
3 months thereafter. Patients were staged according to the 2002
criteria of the American Joint Committee on Cancer. This study
was approved by the hospital’s Institutional Review Board.2.2. RT and CRT regimensPORT was delivered at 2 Gy per fraction, 5 days per week,
at a total dose of 60e66 Gy to the primary site and/or positiveneck levels and 50 Gy to the N0 neck levels. Patients in the
organ preservation group received RT under the same RT
schedule with a total dose of 70 Gy to the primary site and
gross lymphadenopathy (1 cm), and 50 Gy to the N0 neck.
Both sides of the neck were included in treatment portals and
RT was administered with 6-MV X-rays from a linear accel-
erator. Most of the RT techniques used were initial 2D fol-
lowed by 3D boost after 56 Gy. Ten patients received
intensity-modulated RT, and accelerated fractionation was not
used.
Cisplatin-based induction chemotherapy was given mainly
to those patients with bulky T3e4 primary tumors and/or neck
diseases. In primary concurrent chemoradiotherapy (CCRT)
treatment, weekly cisplatin (20 mg/m2) and 5-fluorouracil
(400 mg/m2) were delivered concurrently with the RT. In
postoperative concurrent chemoradiotherapy (POCCRT)
treatment, the chemotherapy regimen consisted of weekly
cisplatin (30 mg/m2) and daily oral tegafureuracil (250 mg/
m2) concurrently with PORT.2.3. Statistical analysisLocal and regional controls were defined as no evidence of
disease at the primary site and the neck. Differences in the
pretreatment and treatment variables between the two groups
were determined using the Chi-square or Fisher exact test and
t test. The rates of disease-specific survival (DSS) and overall
survival (OS) were calculated using the KaplaneMeier prod-
uct limit method and compared by the logrank test. Follow-up
times were defined as the duration between the date of treat-
ment initiation and the events or last contact. DSS was defined
as the time to death from cancer or treatment-related events.
Functional results were evaluated by long-term dependency on
feeding tubes for nutrition and tracheostomy for breathing.
Major complications were defined as treatment-related events
that necessitated a second operation, prolonged hospitaliza-
tion, or were life-threatening. All analyses were performed
using the Statistical Package for the Social Sciences software
version 17.0 (SPSS Inc., Chicago, IL, USA). All tests were
two sided, and results were considered significant at p < 0.05.3. Results3.1. Patient characteristicsThe characteristics of the patients are summarized in
Table 1. Of the 105 patients in our study, 40 (38.1%) had
locally advanced T3e4 tumors and 71 (67.6%) had advanced
stage IIIeIV disease at initial diagnosis. Forty-three patients
(41.0%) were treated with primary surgery with or without
adjuvant therapy, and 62 patients (59.0%) were treated with
RT/CRT organ preservation. There were no differences be-
tween the two groups in terms of age, gender, T and N clas-
sifications, TNM stage, and histological differentiation. The
treatment paradigm changed significantly at our institute
before and after 2002. Only 35.3% of the patients underwent
Table 1
Patient characteristics by treatment group.
Variable All patients (n ¼ 105) Organ preservation (n ¼ 62)a Primary surgery (n ¼ 43) p
No. (%) No. (%) No. (%)
Mean age (range) (y) 54.3 (30e83) 54.8 (30e83) 53.7 (34e81) 0.670
Gender
Male 89 (84.8) 52 (83.9) 37 (86.0) d
Female 16 (15.2) 10 (16.1) 6 (14.0) d
T classification
T1e2 65 (61.9) 39 (62.9) 26 (60.5) d
T3e4 40 (38.1) 23 (37.1) 17 (39.5) d
N classification
N0e1 53 (50.5) 28 (45.2) 25 (58.1) d
N2e3 52 (49.5) 34 (54.8) 18 (41.9) d
Stage
IeII 34 (32.4) 17 (27.4) 17 (39.5) d
IIIeIV 71 (67.6) 45 (72.6) 26 (60.5) d
Histological grade
WD-MD 46 (43.8) 22 (35.5) 24 (55.8) d
PD 20 (19.0) 11 (17.7) 9 (20.9) d
Unknown 39 (37.1) 29 (46.8) 10 (23.3) d
MD ¼ moderately differentiated; PD ¼ poorly differentiated; WD ¼ well differentiated.
a Patients undergoing tumor tonsillectomy followed by radiotherapy/chemoradiotherapy were grouped into the organ preservation group.
Table 2
Treatment and outcomes by treatment group.
Organ
preservation (%)
Primary
surgery (%)
p
(n ¼ 62) (n ¼ 43)
Neck dissection
Yes 24.2 88.4 <0.001
No 75.8 11.6
Chemotherapy
Yes 62.9 11.6 <0.001
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to 81.5% of the patients after 2002 ( p < 0.001).
Of the 43 patients in the primary surgery group, mandibular
surgery to approach the primary tumor was performed in 39
patients (90.7%), including mandibulotomy in 20 patients
(46.5%) and marginal or segmental mandibulectomy in 19
patients (44.2%). Reconstructive surgeries were required to
repair oropharyngeal defects in 35 patients (81.4%). Eighteen
patients (41.9%) were treated with surgery alone, while 20
(46.5%) and 5 (11.6%) patients received adjuvant PORT and
POCCRT, respectively, mainly due to the presence of adverse
pathologic features.
Of the 62 patients in the organ preservation group, 23
(37.1%) received RT alone, 18 (29.0%) received CCRT, and 21
(33.9%) received induction chemotherapy with CCRT. Twenty
patients (32.3%) received a tumor tonsillectomy before
definitive RT/CRT treatment. Seven patients received neck
dissection for advanced N2e3 presentation before definitive
RT/CRT. Eight patients received planned neck dissection for
residual neck mass after completion of RT/CRT, and one
(12.5%) of them tested positive for SCC.No 37.1 88.4
Mean RT dose (range) (Gy) 67.4 (52e76) 61.2 (56e66) <0.001
Median follow-up (range)a (mo) 82.7 (6e170) 108.2 (8e146) 0.2823.2. Oncologic results
Disease control
Local control 79.0 88.4 0.212
Regional control 88.7 86.0 0.684
Distant metastasis 12.9 16.3 0.627
5-year survival
Disease-specific survival 72.8 68.9 0.774
Overall survival 64.9 62.9 0.667
Functional results
Feeding tube dependent 12.9 14.0 0.876
Tracheostomy dependent 6.6 2.3 0.401
Major complications 17.7 27.9 0.216
RT ¼ radiotherapy.
a For surviving patients.The median follow-up times of the surviving patients were
108.2 and 82.7 months for the primary surgery and organ
preservation groups, respectively. Treatment details and out-
comes are summarized in Table 2. Neck dissection was pri-
marily performed on patients in the primary surgery group,
while chemotherapy was used with significantly greater fre-
quency in the organ preservation group ( p < 0.001). In
addition, patients in the organ preservation group received
significantly higher doses of radiation compared with those in
the primary surgery group ( p < 0.001). However, diseasecontrol was equivalent between the two groups. There were no
significant differences in local control ( p ¼ 0.212), regional
control ( p ¼ 0.684), and distant metastasis ( p ¼ 0.627). The
5-year DSS rates were 68.9% and 72.8% ( p ¼ 0.744), and the
5-year OS rates were 62.9% and 64.9% ( p ¼ 0.667) in the
primary surgery group and organ preservation group, respec-
tively (Fig. 1A and B). Taken together, all oncologic results
were similar regardless of whether the patients were treated
with primary surgery or RT/CRT organ preservation.
Fig. 1. (A) Disease-specific survival and (B) overall survival rates in the treatment group of 105 patients with tonsillar squamous cell carcinoma.
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Disease control, survival, and functional results in the patients with T3e4
tumors by treatment group.
Organ
preservation (%)
Primary
surgery (%)
pFunctional results were determined by the dependence on
feeding tubes and tracheostomy at least 6 months after com-
pletion of treatment. As shown in Table 2, feeding tube de-
pendency was observed in 14.0% and 12.9% ( p ¼ 0.876), and
tracheostomy dependency was observed in 2.3% and 6.6%
( p ¼ 0.401) of patients in the primary surgery group and the
organ preservation group, respectively. The only factor pre-
dicting feeding tube dependency and tracheostomy de-
pendency was advanced T3e4 classifications ( p ¼ 0.001 and
0.006, respectively). Major complications occurred in 12 pa-
tients (27.9%) in the primary surgery group and 11 patients
(17.7%) in the organ preservation group ( p ¼ 0.216). Man-
dibular osteoradionecrosis was the most common type of
major complication in both treatment groups (Table 3). Flap
failure, severe wound infection, and pneumonia occurred
mostly in the primary surgery group, while pharyngeal
bleeding, renal failure, and gastrointestinal bleeding were only
observed in the organ preservation group.Table 3
Major complications by treatment group.
Organ
preservation, no. (%)
Primary
surgery, no. (%)
Mandibular ORN 6 (9.6) 6 (14.0)
Flap failure 0 (0) 3 (7.0)
Severe wound infection 1 (1.6) 2 (4.7)
Pneumonia 0 (0) 1 (2.3)
Pharyngeal bleeding 2 (3.2) 0 (0)
Renal failure 1 (1.6) 0 (0)
GI bleeding 1 (1.6) 0 (0)
Total 11 (17.7) 12 (27.9)
GI ¼ gastrointestinal; ORN ¼ osteoradionecrosis.3.4. Treatment results of locally advanced tumorsAdvanced T classification (T3e4) was the only significant
predictor of worse DSS ( p ¼ 0.007) and OS ( p ¼ 0.012) in
this study. Consequently, further analysis was carried out on
this poorly performing subgroup (Table 4). Although T3e4
patients treated with primary surgery demonstrated a trend
toward better local control (88.2% vs. 69.6%, p ¼ 0.256) and
higher distant metastasis rates (41.2% vs. 17.4%, p ¼ 0.153),
neither were statistically significant. There were no significant
differences in the 5-year DSS rate ( p ¼ 0.638), and the 5-year
OS rate ( p ¼ 0.921) between those treated with primary
surgery and RT/CRT organ preservation. Functional outcomes(n ¼ 23) (n ¼ 17)
N2e3 65.2 64.7 0.973
Chemotherapy 87.0 17.6 <0.001
Mean RT dose (range) (Gy) 69.7 (60e76) 61.6 (59e66) <0.001
Disease control
Local control 69.6 88.2 0.256
Regional control 82.6 88.2 0.978
Distant metastasis 17.4 41.2 0.153
5-year survival
Disease-specific survival 62.8 46.3 0.638
Overall survival 51.5 46.3 0.921
Functional results
Feeding tube dependent 21.7 35.3 0.477
Tracheostomy dependent 18.2 5.9 0.363
Major complications 17.4 35.3 0.274
RT ¼ radiotherapy.
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( p ¼ 0.363), and major complication rates ( p ¼ 0.274) were
also similar between the two groups.3.5. Role of tonsillectomy in organ preservation
treatmentTwenty (32.3%) of the 62 patients in the organ preservation
group underwent tumor tonsillectomy before RT/CRT treat-
ment. Nineteen (95%) of the 20 patients had early T1e2 tu-
mors, and 12 (60%) had N0e1 classification at initial
diagnosis (Table 5). Significantly fewer patients received
chemotherapy (20.0% vs. 83.3%, p < 0.001), and the RT dose
was also significantly lower in those patients undergoing
tumor tonsillectomy ( p < 0.001). According to the surgical
records, tumor tonsillectomy with a confident surgical margin
was achieved in three (15%) cases. The final reports of
pathological studies revealed that surgical margin was ade-
quate in only one (5%) patient, close or positive in 10 (50%),
and uncertain in nine (45%). After long-term follow-up, the
local control rate was not significantly improved with tumor
tonsillectomy (85% vs. 76.2%, p ¼ 0.520). There were no
significant improvements in regional and distant controls, and
5-year DSS and OS rates (Fig. 2A and B) among those with or
without tumor tonsillectomy. The differences in functional
outcomes and major complications were also not significant
(Table 5).
4. Discussion
Tonsillar SCC usually responds well to CRT, and there has
been widespread interest in performing such organ preserva-
tion treatment in recent years.6,13 Chen et al13 analyzed the
primary treatment modalites of oropharyngeal SCC in the
United States from 1985 to 2001, and found that the use of
cancer-directed surgery remained stable, whereas CRT wasTable 5
Role of tonsillectomy in the organ preservation group (n ¼ 62).
No tonsillectomy
(%)
Tonsillectomy
(%)
p
(n ¼ 42) (n ¼ 20)
T1e2 47.6 95 <0.001
N0e1 38.1 60 0.105
Chemotherapy 83.3 20.0 <0.001
Mean RT dose (range) (Gy) 68.9 (52e76) 64.1 (54e70) <0.001
Disease control
Local control 76.2 85.0 0.520
Regional control 85.7 95.0 0.412
Distant metastasis 14.3 10.0 0.978
5-year survival
Disease-specific survival 69.4 80.0 0.707
Overall survival 62.9 70.0 0.745
Functional results
Feeding tube dependent 16.7 5.0 0.258
Tracheostomy dependent 9.8 0.0 0.293
Major complications 14.3 25.0 0.311
RT ¼ radiotherapy.increasingly prevalent and RT alone significantly decreased.
The optimal treatment for tonsillar SCC remains controversial
as no randomized studies have compared primary surgery and
RT/CRT organ preservation. At our institute, the treatment
paradigm for tonsillar SCC changed dramatically after 2002.
The proportion of patients treated with primary surgery
decreased significantly from 64.7% to 18.5% after 2002, while
those treated with RT/CRT organ preservation increased sig-
nificantly from 35.3% to 81.5% ( p < 0.001). Thus, matched
patient samples in T or N classification were available for this
retrospective study, providing a reliable comparison with low
selection bias between the two groups (Table 1). Our results
show that primary surgery can achieve equivalent results as
organ preservation treatment for tonsillar SCC (Table 2). This
indicates that primary surgery with or without adjuvant ther-
apy remains a treatment choice for tonsillar SCC.
It is generally accepted that early T1e2 tonsillar SCC can
be effectively treated with either surgery or RT alone.2 We thus
further analyzed the 40 patients with advanced T3e4 tumors.
In the primary surgery group, slightly better local control,
more distant metastasis, higher feeding tube dependency and
lower tracheostomy dependency, and more major complica-
tions were observed, compared with the organ preservation
group (Table 4). However, none of the differences were sta-
tistically significant. This implies a similar efficacy between
the two treatment groups, even in advanced T3e4 tonsillar
SCC.
The optimal treatment for advanced tonsillar SCC is con-
troversial. Parsons et al5 conducted a comprehensive literature
review demonstrating similar oncological outcomes with both
treatment modalities; however, the severe complication rate
was significantly higher in the surgery group. In this study, the
major complication rate in the primary surgery group was
slightly but not significantly higher compared with the organ
preservation group ( p ¼ 0.216, Table 2). Mandibular osteor-
adionecrosis was the most common complication encountered
in both treatment groups, because 25 (58.1%) patients in the
primary surgery group required PORT or POCCRT (Table 3).
However, other types of complications were distributed dif-
ferentially between the two groups.
Whether transoral tonsillectomy before RT/CRT is the
definitive treatment or the debulking management has long
been debated clinically. In this study, although 19 (95%) of the
20 patients treated with tumor tonsillectomy had early T1e2
tumors, adequate surgical and pathological margins were
hardly achieved, occurring in only three (15%) and one (5%)
patient, respectively. Moreover, the mean RT dose in these 20
patients was significantly higher than in the primary surgery
group (64.1 vs. 61.2 Gy, p ¼ 0.021), and nine (45%) of them
even received a dose higher than 66 Gy. Therefore, we grou-
ped these 20 patients into the organ preservation group, con-
sidering RT/CRT as the primary treatment and tumor
tonsillectomy as a debulking procedure. To evaluate the role of
this debulking procedure, we compared their treatment results
with the other 42 patients in the organ preservation group.
Interestingly, tumor tonsillectomy did not contribute to im-
provements in oncologic outcomes, functional results, and
Fig. 2. (A) Disease-specific survival and (B) overall survival according to tumor tonsillectomy in the organ preservation group (n ¼ 62).
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transoral tumor tonsillectomy, even if feasible, is not beneficial
if organ preservation treatment is chosen.
Because of the retrospective design, human papillomavirus
(HPV) infection status was not available in this study. HPV
has been reported to play an important role in the pathogenesis
of tonsillar SCC, and HPV-positive tumors have been shown to
be associated with a better prognosis and higher radio-
sensitivity.14,15 It is reasonable to postulate that HPV-positive
tonsillar SCCs may not require pre-RT/CRT tonsillectomy
because of the superior radiosensitivity. The prevalence rate of
HPV-related tonsillar SCCs has been reported to be lower in
Chinese patients.16e18 In a recent study, Chuang et al18 found
no significant prognostic impact of HPV infection in Chinese
patients treated with primary surgery. Thus, the prognostic role
of HPV infection in surgical patients remains to be elucidated.
Routine screening for HPV status should be advocated to
confirm its role in treatment selection for tonsillar SCC.
A major limitation of this study is the lack of detailed
quality of life (QOL) analysis due to the retrospective study
design, because functional outcome evaluation by feeding tube
and tracheostomy dependency may not accurately reflect the
patient’s QOL. Because both primary surgery and RT/CRT
organ preservation demonstrated equivalent oncological out-
comes, QOL analysis may thus play a crucial role in future
treatment selection. Mowry et al19 and Pourel et al20 reported
that long-term QOL for oropharyngeal cancer is similar,
regardless of whether the patients received CRT or primary
surgery. Tschudi et al21 reported that patients who were sur-
gically treated had less pain, and fewer social eating and
mouth opening problems compared with the nonsurgically
treated patients. These results indicate that further prospective
studies in a large patient population are warranted to clarify
this important issue.
In conclusion, both primary surgery and RT/CRT organ
preservation are effective treatments for tonsillar SCC, with
equivalent outcome efficacy. Single modality treatment, eithersurgery or RT/CRT, can be arranged for stage IeII diseases.
Although in recent years RT/CRT is used more frequently for
stage IIIeIV tonsillar SCC, primary surgery combined with
adjuvant therapy still achieves equivalent outcomes. There-
fore, treatment selection should be based on multidisciplinary
pretreatment counseling and the facilities and personnel
available at each institution. Tumor tonsillectomy before
definitive RT/CRT organ preservation does not contribute to
improved treatment outcomes, and is not indicated for patients
with a pathological diagnosis of tonsillar SCC if RT/CRT
organ preservation is chosen as the primary treatment.
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